BRAF and metastatic melanoma: In 2020, the FDA approved the first immune-combined dual-targeted triple-drug regimen, vemurafenib in combination with cobimetinib plus the programmed death ligand 1 (PD-L1) inhibitor atezolizumab, for first-line treatment of patients with BRAF-V600-mutation-positive, unresectable, or metastatic melanoma.114